Johns Hopkins ABX Guide
Raxibacumab
INDICATIONS
FDA
FDA
- Treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs
- Prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: May 2, 2020
Citation
Dzintars, Kathryn. "Raxibacumab." Johns Hopkins ABX Guide, The Johns Hopkins University, 2020. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540745/all/Raxibacumab.
Dzintars K. Raxibacumab. Johns Hopkins ABX Guide. The Johns Hopkins University; 2020. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540745/all/Raxibacumab. Accessed December 11, 2023.
Dzintars, K. (2020). Raxibacumab. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540745/all/Raxibacumab
Dzintars K. Raxibacumab [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2020. [cited 2023 December 11]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540745/all/Raxibacumab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Raxibacumab
ID - 540745
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2020/05/02/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540745/all/Raxibacumab
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
